Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
/ adverse effects
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Female
Filgrastim
/ therapeutic use
Granulocyte Colony-Stimulating Factor
/ therapeutic use
Hematologic Agents
/ therapeutic use
Humans
Information Storage and Retrieval
Leukemia, Myeloid, Acute
/ epidemiology
Lymphoma, Non-Hodgkin
/ drug therapy
Male
Medicare
Myelodysplastic Syndromes
/ epidemiology
Neoplasms, Second Primary
/ epidemiology
Neutropenia
/ chemically induced
Polyethylene Glycols
/ therapeutic use
Rituximab
/ adverse effects
SEER Program
United States
/ epidemiology
acute myeloid leukemia
epidemiology
granulocyte colony-stimulating factors
myelodysplastic syndrome
non-Hodgkin lymphoma
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
received:
03
09
2018
revised:
30
10
2018
accepted:
08
11
2018
pubmed:
15
12
2018
medline:
31
12
2019
entrez:
15
12
2018
Statut:
ppublish
Résumé
Granulocyte colony-stimulating factors (G-CSFs), which are used for the prevention of complications from chemotherapy-related neutropenia, are linked to the risk of developing second primary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The objective of this study was to examine the correlation between using a specific G-CSF agent and the risk of MDS/AML among older patients with non-Hodgkin lymphoma (NHL). This was a retrospective cohort study of adults aged >65 years who were diagnosed with first primary NHL between 2001 and 2011. With data from the Surveillance, Epidemiology, and End Results-Medicare-linked database, adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for the risk of MDS/AML associated with the receipt of G-CSF(filgrastim and pegfilgrastim) in Cox proportional-hazards models, which were stratified according to treatment accounting for confounding by indication. Among 18,245 patients with NHL patients who had a median follow-up of 3.5 years, 56% received chemotherapy and/or immunotherapy, and G-CSF was most commonly used in those who received rituximab plus multiple chemotherapy regimens (77%). Subsequent MDS/AML diagnoses were identified in 666 patients (3.7%). A modest increased risk of MDS/AML was observed with the receipt of G-CSF (HR, 1.28; 95% CI, 1.01-1.62) and a trend was observed with increasing doses (P A higher of MDS/AML was observed in patients with NHL risk among those who received G-CSF that was specific to the use of filgrastim (≥10 doses), but not pegfilgrastim. Neutropenia prophylaxis is an essential component of highly effective NHL treatment regimens. The differential risk related to the types of G-CSF agents used warrants further study given their increasing use and newly available, US Food and Drug Administration-approved, biosimilar products.
Sections du résumé
BACKGROUND
Granulocyte colony-stimulating factors (G-CSFs), which are used for the prevention of complications from chemotherapy-related neutropenia, are linked to the risk of developing second primary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The objective of this study was to examine the correlation between using a specific G-CSF agent and the risk of MDS/AML among older patients with non-Hodgkin lymphoma (NHL).
METHODS
This was a retrospective cohort study of adults aged >65 years who were diagnosed with first primary NHL between 2001 and 2011. With data from the Surveillance, Epidemiology, and End Results-Medicare-linked database, adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for the risk of MDS/AML associated with the receipt of G-CSF(filgrastim and pegfilgrastim) in Cox proportional-hazards models, which were stratified according to treatment accounting for confounding by indication.
RESULTS
Among 18,245 patients with NHL patients who had a median follow-up of 3.5 years, 56% received chemotherapy and/or immunotherapy, and G-CSF was most commonly used in those who received rituximab plus multiple chemotherapy regimens (77%). Subsequent MDS/AML diagnoses were identified in 666 patients (3.7%). A modest increased risk of MDS/AML was observed with the receipt of G-CSF (HR, 1.28; 95% CI, 1.01-1.62) and a trend was observed with increasing doses (P
CONCLUSIONS
A higher of MDS/AML was observed in patients with NHL risk among those who received G-CSF that was specific to the use of filgrastim (≥10 doses), but not pegfilgrastim. Neutropenia prophylaxis is an essential component of highly effective NHL treatment regimens. The differential risk related to the types of G-CSF agents used warrants further study given their increasing use and newly available, US Food and Drug Administration-approved, biosimilar products.
Identifiants
pubmed: 30548485
doi: 10.1002/cncr.31914
pmc: PMC6420387
mid: NIHMS998120
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Hematologic Agents
0
Granulocyte Colony-Stimulating Factor
143011-72-7
pegfilgrastim
3A58010674
Polyethylene Glycols
3WJQ0SDW1A
Rituximab
4F4X42SYQ6
Filgrastim
PVI5M0M1GW
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143-1154Subventions
Organisme : NCI NIH HHS
ID : HHSN261201000035C
Pays : United States
Organisme : NIMHD NIH HHS
ID : R21 MD011439
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000035I
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002003
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000034C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000140C
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002002
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U58 DP003862
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR000048
Pays : United States
Informations de copyright
© 2018 American Cancer Society.
Références
J Clin Oncol. 2000 Feb;18(3):498-509
pubmed: 10653865
Eur J Cancer. 1993;29A(3):319-24
pubmed: 7691119
Cancer. 1990 Jul 1;66(1):80-8
pubmed: 2354413
Blood. 2000 Mar 1;95(5):1588-93
pubmed: 10688812
J Oncol Pract. 2017 Sep;13(9_suppl):24s-31s
pubmed: 28898593
J Clin Oncol. 2015 Oct 1;33(28):3199-212
pubmed: 26169616
Infect Control Hosp Epidemiol. 1997 Nov;18(11):771-3
pubmed: 9397374
Blood. 2011 Feb 17;117(7):2137-45
pubmed: 21127174
N Engl J Med. 1995 Aug 24;333(8):487-93
pubmed: 7542747
Haematologica. 2007 Oct;92(10):1389-98
pubmed: 17768113
J Natl Compr Canc Netw. 2005 Jul;3(4):557-71
pubmed: 16038646
Ann Oncol. 2016 Sep;27(suppl 5):v111-v118
pubmed: 27664247
Blood. 2005 Jun 15;105(12):4573-5
pubmed: 15741224
J Clin Oncol. 2006 Jul 1;24(19):3187-205
pubmed: 16682719
Haematologica. 2008 Sep;93(9):1335-42
pubmed: 18698083
Breast Cancer Res Treat. 2013 Dec;142(3):629-36
pubmed: 24265034
Semin Oncol. 2008 Aug;35(4):418-29
pubmed: 18692692
Clinicoecon Outcomes Res. 2010;2:37-45
pubmed: 21935313
Med Care. 2002 Aug;40(8 Suppl):IV-3-18
pubmed: 12187163
N Engl J Med. 1991 Jul 18;325(3):164-70
pubmed: 1711156
Br J Haematol. 2006 Dec;135(5):642-50
pubmed: 17054431
Hematology Am Soc Hematol Educ Program. 2007;:453-9
pubmed: 18024664
Clin Infect Dis. 2011 Feb 15;52(4):e56-93
pubmed: 21258094
Eur J Cancer. 2011 Jan;47(1):8-32
pubmed: 21095116
Cancer. 2010 Nov 15;116(22):5279-89
pubmed: 20665502
Bone Marrow Transplant. 2015 Mar;50(3):334-40
pubmed: 25599171
Br J Haematol. 2007 Apr;137(1):77-8; author reply 79-80
pubmed: 17359373
Br J Haematol. 1999 Sep;106(4):1020-6
pubmed: 10520006
P T. 2010 Mar;35(3):148-57
pubmed: 20442809
Blood. 2011 Jun 30;117(26):7121-5
pubmed: 21531980
N Engl J Med. 2006 May 11;354(19):2034-45
pubmed: 16687716
Blood. 2006 Jun 15;107(12):4628-35
pubmed: 16497969
J Clin Oncol. 2015 Nov 1;33(31):3641-9
pubmed: 26304885
Blood. 2003 Jul 1;102(1):43-52
pubmed: 12623843
J Clin Epidemiol. 2000 Dec;53(12):1258-67
pubmed: 11146273
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
Semin Oncol. 2013 Dec;40(6):666-75
pubmed: 24331189
J Clin Oncol. 1996 Feb;14(2):565-71
pubmed: 8636772
Leukemia. 2010 Dec;24(12):2056-62
pubmed: 20962860
Bone Marrow Transplant. 2003 Aug;32(3):317-24
pubmed: 12858205
Leuk Lymphoma. 2001 Feb;40(5-6):499-509
pubmed: 11426523
Med Care. 2015 Aug;53(8):e58-64
pubmed: 23552436
Blood. 2007 Jul 15;110(2):695-708
pubmed: 17389762
Clin Pharmacokinet. 2011 May;50(5):295-306
pubmed: 21456630
Oncogene. 2004 Aug 23;23(38):6404-28
pubmed: 15322514
Blood. 2013 Apr 11;121(15):2996-3004
pubmed: 23412096
J Clin Oncol. 2003 Mar 1;21(5):897-906
pubmed: 12610191
Ann Intern Med. 1985 Aug;103(2):195-200
pubmed: 4014901
J Natl Cancer Inst. 2007 Feb 7;99(3):183-6
pubmed: 17284707
J Natl Cancer Inst. 2007 Feb 7;99(3):196-205
pubmed: 17284714
J Clin Oncol. 2006 Apr 1;24(10):1568-74
pubmed: 16520465
J Natl Cancer Inst. 1993 Dec 1;85(23):1932-7
pubmed: 8230284
J Clin Oncol. 2007 Sep 1;25(25):3871-6
pubmed: 17664457
Ann Oncol. 2002 Mar;13(3):450-9
pubmed: 11996478
Blood. 1996 May 1;87(9):3625-32
pubmed: 8611686
J Clin Oncol. 2010 Jun 10;28(17):2914-24
pubmed: 20385991
Breast Cancer Res Treat. 2015 Nov;154(1):133-43
pubmed: 26450505
J Natl Cancer Inst. 2013 Oct 2;105(19):1456-62
pubmed: 23940288
Cancer Res. 1983 Apr;43(4):1891-8
pubmed: 6572558
N Engl J Med. 2017 Dec 7;377(23):2290-2292
pubmed: 29211670